Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 506-516

  Chen, Buyuan ^a,b   Chen, Xinji ^a,b   Wu, Xiwei ^a   Wang, Xiaoling ^a   Wang, Yingjia ^a,c   Lin, Ting Yu ^a   Kurata, Jessica ^a   Wu, Jun ^a   Vonderfecht, Steven ^a   Sun, Guihua ^a   Huang, He ^c   Yee, Jiing Kuan ^a,b   Hu, Jianda ^b   Lin, Ren Jang ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Cancer; Extracellular matrix; Gene editing; MicroRNA; MiR 21; TALEN

Indexed keywords

CISPLATIN; JAGGED1; MASPIN; MESSENGER RNA; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN PDCD4; SMAD7 PROTEIN; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG; ENDONUCLEASE; MICRORNA; MIRN21 MICRORNA, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL TRANSFORMATION; COL4A1 GENE; CONTROLLED STUDY; DRUG MECHANISM; EXTRACELLULAR MATRIX; FEMALE; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE ISOLATION; GENE ONTOLOGY; GENETIC SCREENING; GENOTYPE ENVIRONMENT INTERACTION; HELA CELL LINE; HUMAN; HUMAN CELL; JAG1 GENE; MASPIN GENE; MOLECULAR CLONING; MOUSE; NONHUMAN; ONCOGENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SERPINB5 GENE; SMAD7 GENE; TGFBI GENE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; UTERINE CERVIX TUMOR;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENDONUCLEASES; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919474075     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.034     Document Type: Article

References (70)

1. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
2. Krichevsky A.M., Gabriely G. miR-21: a small multi-faceted RNA. J. Cell. Mol. Med 2009, 13:39-53.
3. Kumarswamy R., Volkmann I., Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011, 8:706-713.
4. Buscaglia L.E., Li Y. Apoptosis and the target genes of microRNA-21. Chin. J. Cancer 2011, 30:371-380.
5. Wang S.E., Lin R.-J. MicroRNA and HER2-overexpressing cancer. MicroRNA 2013, 2:137-147.
6. Hatley M.E., Patrick D.M., Garcia M.R., Richardson J.A., Bassel-Duby R., van Rooij E., et al. Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell 2010, 18:282-293.
7. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
8. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., et al. Inflammation, L.S.C.R.P. host response to injury, genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3507-3512.
9. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
10. Ishida M., Selaru F.M. miRNA-based therapeutic strategies. Curr. Anesthesiol. Rep 2013, 1:63-70.
11. Cheng Y., Zhang C. MicroRNA-21 in cardiovascular disease. J. Cardiovasc. Transl. Res 2010, 3:251-255.
12. Villar A.V., Garcia R., Merino D., Llano M., Cobo M., Montalvo C., et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int. J. Cardiol 2013, 167:2875-2881.
13. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
14. Patrick D.M., Montgomery R.L., Qi X., Obad S., Kauppinen S., Hill J.A., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest 2010, 120:3912-3916.
15. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
16. Hockemeyer D., Wang H., Kiani S., Lai C.S., Gao Q., Cassady J.P., et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol 2011, 29:731-734.
17. Urnov F.D., Miller J.C., Lee Y.L., Beausejour C.M., Rock J.M., Augustus S., et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005, 435:646-651.
18. Gaj T., Gersbach C.A., Barbas C.F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013, 31(7):397-405.
19. Pauwels K., Podevin N., Breyer D., Carroll D., Herman P. Engineering nucleases for gene targeting: safety and regulatory considerations. New Biotechnol 2013, 31:18-27.
20. Boch J., Scholze H., Schornack S., Landgraf A., Hahn S., Kay S., et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009, 326:1509-1512.
21. Cermak T., Doyle E.L., Christian M., Wang L., Zhang Y., Schmidt C., et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011, 39:e82.
22. Li T., Huang S., Zhao X., Wright D.A., Carpenter S., Spalding M.H., et al. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res 2011, 39:6315-6325.
23. Miller J.C., Tan S., Qiao G., Barlow K.A., Wang J., Xia D.F., et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol 2011, 29:143-148.
24. Guschin D.Y., Waite A.J., Katibah G.E., Miller J.C., Holmes M.C., Rebar E.J. A rapid and general assay for monitoring endogenous gene modification. Methods Mol. Biol 2010, 649:247-256.
25. Taniguchi K., Kajiyama T., Kambara H. Quantitative analysis of gene expression in a single cell by qPCR. Nat. Methods 2009, 6:503-506.
26. de Hoon M.J., Imoto S., Nolan J., Miyano S. Open source clustering software. Bioinformatics 2004, 20:1453-1454.
27. Robinson M.D., Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol 2010, 11:R25.
28. Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26:139-140.
29. Bullard J.H., Purdom E., Hansen K.D., Dudoit S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinformatics 2010, 11:94.
30. da Huang W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc 2009, 4:44-57.
31. Bedell V.M., Wang Y., Campbell J.M., Poshusta T.L., Starker C.G., Krug R.G., et al. In vivo genome editing using a high-efficiency TALEN system. Nature 2012, 491:114-118.
32. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14863-14868.
33. van Dongen S., Abreu-Goodger C., Enright A.J. Detecting microRNA binding and siRNA off-target effects from expression data. Nat. Methods 2008, 5:1023-1025.
34. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003, 4:P3.
35. Cher M.L., Biliran H.R., Bhagat S., Meng Y., Che M., Lockett J., et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7847-7852.
36. Liu G., Friggeri A., Yang Y., Milosevic J., Ding Q., Thannickal V.J., et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med 2010, 207:1589-1597.
37. Murata K., Ota S., Niki T., Goto A., Li C.P., Ruriko U.M., et al. p63 - key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis. Exp. Mol. Pathol 2007, 83:367-376.
38. Nakken K.E., Nygard S., Haaland T., Berge K.E., Arnkvaern K., Odegaard A., et al. Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/-) mice harbouring chronic cholangitis. Scand. J. Gastroenterol 2007, 42:1245-1255.
39. Yu H., Konigshoff M., Jayachandran A., Handley D., Seeger W., Kaminski N., et al. Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J. 2008, 22:1778-1789.
40. Pajares M.J., Agorreta J., Salvo E., Behrens C., Wistuba I.I., Montuenga L.M., et al. TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. Br. J. Cancer 2014, 110:1545-1551.
41. Chau B.N., Xin C., Hartner J., Ren S., Castano A.P., Linn G., et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med 2012, 4:121ra118.
42. Huntzinger E., Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet 2011, 12:99-110.
43. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
44. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
45. Tay Y., Song S.J., Pandolfi P.P. The lilliputians and the giant: an emerging oncogenic microrna network that suppresses the PTEN tumor suppressor in vivo. MicroRNA 2013, 2:127-136.
46. Zhou P., Xu W., Peng X., Luo Z., Xing Q., Chen X., et al. Large-scale screens of miRNA-mRNA interactions unveiled that the 3'UTR of a gene is targeted by multiple miRNAs. PLoS ONE 2013, 8:e68204.
47. Li Z., Rana T.M. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov 2014, 13:622-638.
48. Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005, 33:1290-1297.
49. Yao Q., Xu H., Zhang Q.Q., Zhou H., Qu L.H. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem. Biophys. Res. Commun 2009, 388:539-542.
50. Kim Y.K., Wee G., Park J., Kim J., Baek D., Kim J.S., et al. TALEN-based knockout library for human microRNAs. Nat. Struct. Mol. Biol 2013, 20:1458-1464.
51. Uhde-Stone C., Sarkar N., Antes T., Otoc N., Kim Y., Jiang Y.J., et al. A TALEN-based strategy for efficient bi-allelic miRNA ablation in human cells. RNA 2014, 20:948-955.
52. Wang X., Wang Y., Huang H., Chen B., Chen X., Hu J., et al. Precise gene modification mediated by TALEN and single-stranded oligodeoxynucleotides in human cells. PLoS ONE 2014, 9:e93575.
53. Wright D.A., Li T., Yang B., Spalding M.H. TALEN-mediated genome editing: prospects and perspectives. Biochem. J. 2014, 462:15-24.
54. Wang P., Zou F., Zhang X., Li H., Dulak A., Tomko R.J., et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009, 69:8157-8165.
55. Hu R., Wallace J., Dahlem T.J., Grunwald D.J., O'Connell R.M. Targeting human microRNA genes using engineered Tal-effector nucleases (TALENs). PLoS ONE 2013, 8:e63074.
56. Zeng Y., Cullen B.R. Sequence requirements for micro RNA processing and function in human cells. RNA 2003, 9:112-123.
57. Lee H.Y., Doudna J.A. TRBP alters human precursor microRNA processing in vitro. RNA 2012, 18:2012-2019.
58. Ma X., Kumar M., Choudhury S.N., Becker Buscaglia L.E., Barker J.R., Kanakamedala K., et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10144-10149.
59. Masters J.R. HeLa cells 50 years on: the good, the bad and the ugly. Nat. Rev. Cancer 2002, 2:315-319.
60. Adey A., Burton J.N., Kitzman J.O., Hiatt J.B., Lewis A.P., Martin B.K., et al. The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line. Nature 2013, 500:207-211.
61. Landry J.J., Pyl P.T., Rausch T., Zichner T., Tekkedil M.M., Stutz A.M., et al. The genomic and transcriptomic landscape of a HeLa cell line. G3 2013, 3:1213-1224.
62. Greer B.E., Koh W.J., Abu-Rustum N.R., Apte S.M., Campos S.M., Chan J., et al. National Comprehensive Cancer, Cervical cancer. J. Natl. Compr. Canc. Netw 2010, 8:1388-1416.
63. Chen Y., Tsai Y.H., Fang Y., Tseng S.H. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J. Pediatr. Surg 2012, 47:1797-1805.
64. Yang S.M., Huang C., Li X.F., Yu M.Z., He Y., Li J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 2013, 306:162-168.
65. Hiemer S.E., Szymaniak A.D., Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. J. Biol. Chem 2014, 289:13461-13474.
66. Kim H., Hwang J.S., Lee B., Hong J., Lee S. Newly identified cancer-associated role of human neuronal growth regulator 1 (NEGR1). J. Cancer 2014, 5:598-608.
67. Takita J., Chen Y., Okubo J., Sanada M., Adachi M., Ohki K., et al. Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma. Cancer Sci 2011, 102:1645-1650.
68. Zhu H., Luo H., Li Y., Zhou Y., Jiang Y., Chai J., et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J. Clin. Immunol 2013, 33:1100-1109.
69. Adam O., Lohfelm B., Thum T., Gupta S.K., Puhl S.L., Schafers H.J., et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res. Cardiol 2012, 107:278.
70. Hecker L., Logsdon N.J., Kurundkar D., Kurundkar A., Bernard K., Hock T., et al. Reversal of persistent fibrosis in aging by targeting nox4-nrf2 redox imbalance. Sci. Transl. Med 2014, 6:231ra247.